Choosing Between SCIT and SLIT: Trial Efficacy Against Real-World Adherence
A patient ready for a treatment that outlasts daily medication, choosing between the one with broader evidence and the one she can actually keep.
Petra L., a 30-year-old management consultant who travels for work roughly one week out of every four, has had moderate-to-severe perennial allergic rhinitis for over a decade, confirmed sensitized to dust mite, cat dander, and three separate grass and tree pollens on skin testing. She has been on maximized combination pharmacotherapy — intranasal corticosteroid, oral antihistamine, and montelukast during peak pollen months — for the past two years, with adequate but incomplete symptom control, and has started asking directly about immunotherapy specifically because she is tired of daily medication and wants something with a chance of durable, disease-modifying benefit rather than ongoing symptom suppression.
The choice she's actually facing is less about whether immunotherapy works, which isn't in serious dispute for either modality, than about which one she will realistically complete given her specific circumstances. A comparative meta-analysis (Di Bona et al.) found SCIT's effect sizes generally at least as strong as SLIT's across a broad range of studied allergens, and SCIT allows a single custom-mixed regimen covering all of her distinct sensitizations at once — an advantage SLIT, typically limited to single or dual-allergen commercial products, doesn't straightforwardly offer someone sensitized to five separate allergens. The intuition that her travel schedule therefore favors SLIT is the one the real-world data actually contradict. Kiel and colleagues followed 6,486 patients through a national pharmacy database and found three-year persistence of 24% for SCIT against just 7% for SLIT — daily self-administration at home, unsupervised, is abandoned far faster than a scheduled injection someone else is expecting her to keep. Her travel is a real obstacle to the office visits, but the modality it would push her toward is the one patients complete least often.
Petra has no other chronic medical conditions and takes no regular medications besides her current allergy regimen; she has never had a systemic allergic reaction of any kind, including no prior anaphylaxis, which is relevant directly to today's immunotherapy discussion since it means she isn't starting from an elevated baseline risk for a severe reaction during build-up. She has researched both options extensively on her own before this visit and arrives with a specific, informed question rather than an open-ended one — she wants to know not just which modality is generally considered more effective, but which one she will actually be able to finish given her particular schedule.
Two real treatments, and a schedule that only fits one of them cleanly
She's sensitized to five distinct allergens. SCIT lets us build one custom regimen covering all of them at once, and comparative meta-analyses generally find its effect sizes at least as strong as SLIT's across a broad range of allergens — SLIT products are typically limited to one or two allergens, which doesn't cleanly match her actual sensitization profile.
The efficacy comparison matters less than what she'll actually complete — and I want to be careful here, because the obvious inference is the wrong one. Kiel's pharmacy-database cohort found three-year persistence of 24% for SCIT and 7% for SLIT. Sending her to SLIT because she travels would be sending her to the modality patients abandon at more than three times the rate.
And she still travels roughly a week out of every month. That remains a real problem against a years-long build-up and maintenance schedule requiring regular in-office visits. It just isn't a problem SLIT solves.
Then the two of you have converged further than it sounds — efficacy and real-world persistence now point the same direction, and what's left is a logistics problem rather than an evidence problem. Worth saying plainly, because the version of this conversation where her travel schedule quietly selects SLIT would be picking the weaker option on both counts at once.
Two things to check before anyone commits her. Does a commercial SLIT product actually cover a meaningful share of her five sensitizations, or would she need several layered together — at further cost to the adherence that is already the weaker of the two? And can her clinic build maintenance around her travel, monthly rather than weekly injections once she is through build-up, which is precisely the interval Kiel's discontinuation curve suggests is survivable?
Agreed: proceed with custom-mixed SCIT, having confirmed directly — rather than assumed — both that her clinic could schedule maintenance around her travel and that SLIT products couldn't cleanly cover her full sensitization profile.
The disagreement between the allergist and primary care physician was resolved by information, not by one position yielding to the other — the adherence concern was real and worth checking, and once checked, the real-world data pointed the opposite way from the intuition that raised it — leaving her travel schedule as a logistics problem to solve inside SCIT rather than a reason to leave it.